. AF may also represent an inflammatory complication of cancer. Indeed, AF was more commonly observed in patients with elevated postoperative neutrophil counts (OR 3.2, 95% CI 1.3-7.8, p = 0.01), and after open versus laparoscopic colectomy (OR 3.3, 95% CI 1.3-8, p = 0.008), suggesting that open colectomy causes a more severe systemic inflammatory response 9 .
Prophylaxis
Administration of 300 mg of amiodarone intravenously over 20 minutes immediately after surgery for lung cancer and an oral dose of 600mg twice daily during the first five postoperative days reduced the risk of AF by 23% 10 . Nojiri et al 11 reported that patients with elevated BNP levels (> 30 pg/mL) who received low-dose human atrial natriuretic peptide had lower incidence of postoperative AF than patients who received placebo.
Treatment
Landiolol, an ultra-short-acting beta-blocker, when administered to a small group of patients who developed AF after lung resection, experienced a significant reduction in heart rate and early restoration of sinus rhythm as compared to verapamil and digoxin 12 .
Sepsis

Prophylaxis
A recent study investigated the effect of esmolol in patients with septic shock 13 . Although reduction in heart rate may lead to improvement of cardiovascular function, treatment of sinus tachycardia, and consequently potentially prevent AF, the use of esmolol in sepsis is still controversial. Further studies to establish the recommendations regarding prophylaxis are needed 14 .
COPD
Treatment
According to current recommendations, reversal of hypoxemia and acidosis should be the first therapeutic approaches in new-onset AF. However, in patients who become hemodynamically unstable, synchronized cardioversion should be considered, although the strategy for rhythm control may be ineffective until the respiratory decompensation is corrected.
For ventricular rate control, diltiazem or verapamil are the recommended drugs for COPD patients. The use of β-adrenergic agonists and theophylline is discouraged, since they may precipitate atrial fibrillation and make ventricular rate control difficult. Non-selective beta-blockers, sotalol, propafenone and adenosine are contraindicated in patients with bronchospasm 15 .
Obstructive Sleep Apnea
Prognosis
Few studies have investigated the effect of AF on OSA. OSA is associated with increased risk of stroke, but it is not clear whether AF increases the risk of stroke in OSA. The Sleep Heart Health study 16 , a prospective study which followed up 5,422 individuals with no history of stroke for a mean of 8.7 years, reported that OSA increases the risk of stroke, particularly in men in the highest severity quartile (obstructive apnea-hypopnea index > 19: adjusted HR 2.86, 95% CI 1.1-7.4). After secondary analyses that excluded individuals with AF, lower OR for stroke was observed in OSA patients, with no change in overall results, suggesting that AF does not fully explain the association between OSA and AF. However, the proportion of patients with AF in this study was small (2%), and the authors suggested that underdiagnosed paroxysmal AF was a mediating factor.
More recently, a case -control study involving 108 individuals reported a significant association between AF and stroke, even after adjusting for other risk factors (corrected OR 5.34, 95% CI 1.79-17.29) 17 . Further studies to confirm whether AF increases the risk of stroke in patients with OSA are necessary.
Chronic Kidney Disease
Pathophysiology
In addition to cardiovascular diseases, other comorbidities are commonly encountered in AF and CKD. Curiously, the combination of CKD and anemia increases substantially the risk of stroke (HR 5.43, 95% CI 2.04-14.41)
18
, which may be related to an increased risk for AF. In fact, anemia, a common complication of CKD, and CKD are independent risk factors of AF, and a recent study demonstrated a synergic association between CKD and anemia for AF onset 19 .
Treatment
Several international anticoagulation therapy guidelines in CKD are currently available. In 2011, the Kidney Disease Outcomes Quality Initiative recommended that anticoagulation therapy should only be prescribed for patients with CKD as a secondary prevention of stroke and careful monitoring of patients, and not as primary prevention, since these patients were not included in controlled, randomized studies 20 . However, the 2014 AHA/ACC/HRS guidelines support the prescription of warfarin (INR 2.0-3.0) for oral anticoagulation for patients with nonvalvular AF, CHA 2 DS 2 VAS C ≥ 2, and who have ESRD or are on hemodialysis, recognizing that anticoagulation increases the hemorrhagic risk in this population. With respect to AF in moderate to severe CKD with CHA2DS2-VASc ≥ 2, treatment with lower doses of direct thrombin or factor Xa inhibitors may be considered, although safety and efficacy have not been established 15 . 
